FAST NEWS: BlackRock boosts stake in battered WuXi AppTec

2359.HK 603259.SHG
WuXi AppTec has recently come under fire from U.S. politicians who want to ban government-backed projects from buying its services, causing the stock to lose about half of its value this year.

The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from 5.99% to 6.15%, according to a new Hong Kong Stock Exchange filing.

Looking up: Such an increase by a major institutional buyer is usually a favorable sign, implying the investor is positive on the company’s prospects and believes the stock may have some upside.

Take Note: BlackRock did not disclose the average price per share for its latest purchases. But it may have already lost money on the purchases, based on a decline in the stock’s price between March 26 and the latest trading levels this week.

Digging Deeper: Founded in 2000 and listed in Hong Kong and Shanghai in 2018, WuXi AppTec provides pharmaceutical outsourcing services (CXO) covering the entire industry chain from drug discovery to commercialization. The company has steadily expanded its business in recent years and recorded 15 consecutive quarters of year-on-year revenue growth through the third quarter of last year, drawing on growing demand for its R&D and manufacturing services both at home and overseas. But the company has recently come under fire from U.S. politicians who want to ban government-backed projects from buying its services, causing the stock to lose about half of its value this year.

Market Reaction: WuXi AppTec shares rose in early trading on Wednesday and closed up 2.3% at HK$37.6 by the midday break. The stock now trades near the lower end of its 52-week range.

Translation by A. Au

To subscribe to Bamboo Works weekly free newsletter, click here

,
, , , ,

Related Articles

RELATED ARTICLES

  1. WuXi Biologics
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  2. WuXi AppTec mulls gene unit sale to soften U.S. legal blow
    2359.HK 603259.SHG
  3. BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
    2359.HK 603259.SHG
  4. FAST NEWS: BlackRock reduces Kuaishou stake to below 5%
    1024.HK
  5. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  6. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  7. A Drug Company’s Forced Sales, and a Family Feud in Shanghai
    2269.HK 2359.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of the rebound of Chinese fintech lenders

A fintech lender rebound, and a hotel mess

Fintech lenders are entering a new golden era, with Jiayin reporting 46% growth for its core consumer lending business in last year's fourth quarter and forecasting similar gains this year. What's driving this rebound? And hotelier H World is still trying to fix a German acquisition from 2019 that wiped out its profit in the fourth quarter of last year. Will the Chinese hotelier be able to turn around this money-losing offshore asset?
JFIN.US HTHT.US